1. Market Research
  2. > Therapy Industry
  3. > All premium reports
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Publication dates

1-10 of about 2700 reports for phase iii clinical trial

Purchase Reports From Reputable Market Research Publishers

Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020

Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020

  • $ 4950
  • Industry report
  • May 2016
  • by Grand View Research

Global pharmacovigilance market is expected to reach USD 5.51 billion by 2020. Increasing incidence rates of adverse drug reaction and the introduction of stringent drug safety regulations are some key ...

Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • $ 3495
  • Industry report
  • July 2014
  • by Global Data

Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Evolocumab (Acute Coronary Syndrome) - Forecast ...

Pharmacovigilance Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020

Pharmacovigilance Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020

  • $ 5000
  • Industry report
  • December 2015
  • by Future Market Insight Global & Consulting Pvt Ltd

Future Market Insights offers a 6-year forecast of the global pharmacovigilance market between 2015 and 2020. In terms of value, the market is expand at a CAGR of 14.2% during the forecast period. This ...

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Global Clinical Trials Review, H1, 2014

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Global Clinical Trials Review, H1, 2014

  • $ 2500
  • Industry report
  • May 2014
  • by Global Data

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) ...

PCSK9 and Other Novel Hypercholesterolemia Drugs Market, 2014 - 2024

PCSK9 and Other Novel Hypercholesterolemia Drugs Market, 2014 - 2024

  • $ 1899
  • Industry report
  • September 2014
  • by Roots Analysis Private Ltd.

INTRODUCTION Worldwide statistics indicate that there is a high cholesterol burden despite the presence of many cholesterol-lowering drugs in the market. Out of all the available options, statins have ...

Oral Oncolytics Series: Leukemia, 2014 - 2024

Oral Oncolytics Series: Leukemia, 2014 - 2024

  • $ 1899
  • Industry report
  • May 2014
  • by Roots Analysis Private Ltd.

INTRODUCTION Targeted therapeutics is fast emerging as the key focus area in biopharmaceutical industry. Oral targeted therapeutics has attracted many drug developers due to the ease of administration ...

Oncology drugs report - Neupogen and Neulasta - filgrastim franchise - 1991-2015 analysis; 2016-2021 expectations

Oncology drugs report - Neupogen and Neulasta - filgrastim franchise - 1991-2015 analysis; 2016-2021 expectations

  • $ 1000
  • Industry report
  • November 2016
  • by Cancer Research Analytics

“Oncology drugs report - Neupogen and Neulasta - filgrastim franchise - 1991-2015 analysis; 2016-2021 expectations” is a comprehensive report on Neupogen and Neulasta, two market leading drugs (by ...

Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations

Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations

  • $ 500
  • Industry report
  • November 2016
  • by Cancer Research Analytics

Description “Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations” is a comprehensive drug report on the fouth-largest oncology drug by 2015 sales. Revlimid is ...

Iclusig - ponatinib - Oncology drug report - 2013-2015 analysis; 2016-2021 expectations

Iclusig - ponatinib - Oncology drug report - 2013-2015 analysis; 2016-2021 expectations

  • $ 300
  • Industry report
  • December 2016
  • by Cancer Research Analytics

“Iclusig - ponatinib - Oncology drug report - 2013-2015 analysis; 2016-2021 expectations” is a comprehensive drug report on the most controversial drug in recent times. Iclusig is the first and only ...

Oncology drug report - Adcetris - brentuximab vedotin - 2011-2015 analysis; 2016-2021 expectations

Oncology drug report - Adcetris - brentuximab vedotin - 2011-2015 analysis; 2016-2021 expectations

  • $ 500
  • Industry report
  • November 2016
  • by Cancer Research Analytics

“Adcetris: 2011-2015 analysis; 2016-2021 expectations” is a comprehensive report on the first and only approved drug of Seattle Genetics called Adcetris, which is also the first drug approved by the ...

About 5400 reports for phase iii clinical trial

Download Unlimited Documents from Trusted Public Sources

Recro Pharma, Inc. - Company Report, January 2016

  • January 2016
    3 pages
  • Anti Rheumatic  

    Clinical Trial  

  • United States  

View report >

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.